Chemours Co financial statements

Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data Chemours Co files with the SEC in its annual reports.

In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.

Income statement

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	5,400	6,183	6,638	5,526	4,969	6,345	6,831	6,078	5,782	5,808
Cost of revenue	4,297	4,438	4,667	4,463	3,902	4,964	5,215	4,776	4,640	4,906
Gross profit	1,103	1,745	1,971	1,063	1,067	1,381	1,616	1,302	1,142	902
Research and development	81	81	82	80	93	107	118	108	109	108
Selling, general and administrative	946	626	657	548	527	592	710	1,286	598	799
Operating expenses	1,197	764	788	715	700	705	844	1,547	823	966
Interest expense	219	214	195	208	210	185	163	208	263	269
Other non-operating income	267	113	162	-293	21	163	70	91	8	26
Pre-tax income	-11	912	1,155	-124	179	676	741	-318	106	-277
Income tax	-18	165	159	-72	-40	68	163	-66	37	109
Net income to minority interests	0	1	1	0	0			1
Net income	7	746	995	-52	219	608	578	-253	69	-386
EPS, basic	0.04	4.29	5.97	-0.34	1.41	3.92	3.95	-1.70	0.46	-2.57
EPS, diluted	0.04	4.15	5.79	-0.34	1.40	3.83	3.88	-1.70	0.46	-2.57
Shares, basic (weighted)	171	174	167	155	155	155	146	149	149	150
Shares, diluted (weighted)	173	180	172	155	157	159	149	149	150	150
Dividend per share	0.13	0.31	0.71	1.06	1.06	1.06	1.06	1.00	1.00	0.51

Balance sheet

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Cash and equivalents	902	1,556	1,201	943	1,105	1,451	1,102	1,203	713	670
Receivables	742	847	790	602	449	644	509	509	619	562
Inventory	767	935	1,147	1,079	939	1,099	1,404	1,349	1,463	1,569
Other current assets	77	83	84	81	78	75	82	66	71	80
Total current assets	2,553	3,493	3,293	2,777	2,633	3,345	3,214	3,844	3,017	3,001
Property, plant and equipment	2,784	3,008	3,291	3,559	3,474	3,154	3,171	3,207	3,188	3,078
Lease right-of-use assets				294	236	227	240	263	265	271
Goodwill	153	153		153	153	102	102	102	46	46
Intangible assets	17	13	28	21	14	6	13	3	3	2
Other non-current assets	417	453	437	292	405	447	523	664	788	751
Total assets	6,060	7,293	7,362	7,258	7,082	7,550	7,640	8,241	7,509	7,382
Accounts payable	884	1,075	1,137	923	844	1,162	1,233	1,159	1,156	954
Accrued liabilities	872	558	559	484	375	325	300	1,059	396	506
Deferred revenue	76	8	6	7	7	3
Short-term debt	15	15	13	134	21	25	43	51	54	42
Total current liabilities	1,771	1,648	1,709	1,541	1,442	1,858	1,891	2,487	1,820	1,686
Long-term debt	3,529	4,097	3,959	4,026	4,005	3,724	3,590	3,989	4,059	4,099
Lease liabilities				245	194	179	198	208	198	191
Other non-current liabilities	524	475	457	633	295	269	319	329	369	588
Total liabilities	5,956	6,428	6,342	6,563	6,267	6,468	6,533	7,518	6,937	7,131
Total debt	3,591	4,112	3,972	4,026	4,005	3,724	3,590	3,989	4,059	4,099
Paid-in capital	789	837	860	859	890	944	1,016	1,033	1,055	1,074
Retained earnings	-114	579	1,466	1,249	1,303	1,746	2,170	1,781	1,685	1,220
Treasury stock		-116	-750	-1,072	-1,072	-1,247	-1,738	-1,806	-1,804	-1,802
Other comprehensive income	-577	-442	-564	-349	-310	-364	-343	-274	-367	-244
Shareholders' equity	100	860	1,014	689	813	1,081	1,107	721	571	250
Minority interests	4	5	6	6	2	1		2	1	1
Total equity	104	865	1,020	695	815	1,082	1,106	723	572	251
Total liabilities and equity	6,060	7,293	7,362	7,258	7,082	7,550	7,640	8,241	7,509	7,382
Shares outstanding	172	172	161	154	155	152	140	149	149	150

Cash flow statement

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Net income	7	747	996	-52	219	608	578	-252	69	-386
Depreciation and amortization	284	273	284	311	320	317	291	309	292	340
Stock-based compensation	19	29	24	19	16	34	27	18	15	21
Deferred income tax	-111	83	22	-163	-120	-76	20	-143	-31	60
Change in payables						281	105	-74	4	-165
Cash from operations	594	640	1,140	650	807	814	755	556	-633	264
Capital expenditures	-338	-411	-498	-481	-267	-277	-307	-370	-360	-213
Acquisitions	0	0	-37	-10	0	0
Cash from investing	357	-370	-487	-483	-234	220	-284	-229	-353	-206
Debt issued	0	495	520			650	0	648	606	748
Debt repaid	-381	-27	-679
Stock issued	11	31	16	9	16	23	51	19	9
Share buybacks	0	-106	-644	-322	0	-173	-495	-69
Dividends paid	-22	-22	-148	-164	-164	-164	-154	-149	-148	-78
Cash from financing	-396	352	-993	-419	-449	-554	-686	172	-36	-126
Exchange rate effect	-19	32	-15	-6	38	-34	-32	4	-22	29
Net change in cash	536	654	-355	-258	162	446	-247	503	-1,044	-39
Free cash flow	256	229	642	169	540	537	448	186	-993	51
Interest paid	208	208	206	204	208	180	164	223	267	251
Income taxes paid	50	79	75	85	78	149	131	63	82	74

Key metrics

Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $14.46 on September 25, 2026.

Profitability

Metric	Value	How it is calculated
Gross margin	15.3%	Gross profit / revenue.
Pre-tax margin	-0.9%	Pre-tax income / revenue.
Net margin	-5.2%	Net income / revenue.
FCF margin	3.8%	Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin	6.8%	Cash from operations / revenue.
Return on assets (ROA)	-4.3%	Net income / average total assets.
R&D / revenue	1.8%	Research and development expense / revenue.
SG&A / revenue	15.0%	Selling, general and administrative expense / revenue.
Stock-based pay / revenue	0.4%	Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue	3.1%	Capital expenditures / revenue.
D&A / revenue	5.5%	Depreciation and amortization / revenue.

Growth

Metric	Value	How it is calculated
Revenue growth, 1y	0.4%	Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y	-5.3%	Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y	3.2%	Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y	-21.0%	Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y	-17.7%	Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y	-3.3%	Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Net income growth, 1y	-659.4%	Net income vs the same period a year earlier. Only from a positive base.
EPS growth, 1y	-658.7%	EPS vs the same period a year earlier. Only from a positive base.
Operating cash flow CAGR, 3y	-29.5%	Compound annual growth of operating cash flow over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Operating cash flow CAGR, 5y	-20.0%	Compound annual growth of operating cash flow over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Free cash flow CAGR, 3y	-51.5%	Compound annual growth of free cash flow over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Free cash flow CAGR, 5y	-37.6%	Compound annual growth of free cash flow over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Dividend per share growth, 1y	-48.8%	Dividend per share vs the same period a year earlier. Only from a positive base.
Dividend per share CAGR, 3y	-21.6%	Compound annual growth of dividend per share over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Dividend per share CAGR, 5y	-13.6%	Compound annual growth of dividend per share over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y	-56.2%	Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y	-39.1%	Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y	-21.0%	Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y	-1.7%	Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y	-1.1%	Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y	0.8%	Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y	0.0%	Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y	0.3%	Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y	-0.8%	Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.

Balance sheet health

Metric	Value	How it is calculated
Current ratio	1.66x	Current assets / current liabilities.
Quick ratio	0.78x	(Cash + short-term investments + receivables) / current liabilities.
Cash ratio	0.36x	(Cash + short-term investments) / current liabilities.
Debt / assets	53.7%	Total debt / total assets.
Liabilities / assets	100.7%	Total liabilities / total assets.
Net debt	$3.17B	Total debt - cash - short-term investments. Negative means more cash than debt.
Working capital	$1.23B	Current assets - current liabilities.
Goodwill and intangibles / assets	0.6%	(Goodwill + intangible assets) / total assets.
Tangible book value	-$95.0M	Shareholders' equity - goodwill - intangible assets.

Efficiency

Metric	Value	How it is calculated
Asset turnover	0.81x	Revenue / average total assets.
Fixed asset turnover	1.91x	Revenue / average property, plant and equipment.
Inventory turnover	3.38x	Cost of revenue / average inventory.
Days inventory	108 days	365 x average inventory / cost of revenue.
Receivables turnover	7.50x	Revenue / average receivables.
Days sales outstanding	49 days	365 x average receivables / revenue.
Days payables	70 days	365 x average accounts payable / cost of revenue.
Cash conversion cycle	87 days	Days inventory + days sales outstanding - days payables.
Capex / operating cash flow	45.1%	Capital expenditures / cash from operations, when that is positive.

Per share

Metric	Value	How it is calculated
EPS, diluted	-$2.00	Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share	$38.33	Revenue / diluted weighted shares.
FCF per share	$1.44	Free cash flow / diluted weighted shares.
Operating cash flow per share	$2.63	Cash from operations / diluted weighted shares.
Book value per share	-$0.33	Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Tangible book per share	-$0.63	Tangible book value / shares outstanding.
Cash per share	$4.46	(Cash + short-term investments) / shares outstanding.
Dividends / FCF	24.8%	Dividends paid / free cash flow, when free cash flow is positive.

Valuation

Metric	Value	How it is calculated
Market cap	$2.18B	Share price x shares outstanding.
Enterprise value	$5.34B	Market cap + total debt - cash - short-term investments.
P/S	0.38x	Market cap / revenue.
P/FCF	9.98x	Market cap / free cash flow. Only when free cash flow is positive.
P/OCF	5.48x	Market cap / cash from operations, when positive.
EV/Sales	0.92x	Enterprise value / revenue.
EV/FCF	24.5x	Enterprise value / free cash flow, when both are positive.
FCF yield	10.0%	Free cash flow / market cap.
Earnings yield	-14.0%	Net income / market cap (the inverse of P/E).
Dividend yield	2.5%	Dividends paid over the period / market cap.
Shareholder yield	2.5%	(Dividends paid + share buybacks) / market cap.

What was Chemours Co's revenue in fiscal 2025?

Chemours Co reported revenue of $5.81B for fiscal 2025, 0.4% higher than the year before.

Was Chemours Co profitable in fiscal 2025?

No. It reported a net loss of $386.0M.

How much free cash flow did Chemours Co generate in fiscal 2025?

Cash from operations of $264.0M minus capital expenditures of $213.0M left free cash flow of $51.0M.

Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.

Open interactive statements, quarterly figures and charts

Back to Chemours Co